For comparison, the effect of pan-RAFi and the other inhibitors on the growth of four other melanoma cell lines with different mutations in the MAPK pathway (c-KIT mutant M230, BRAF mutant M397, BRAF WT/NRAS WT PB, and NRAS mutant M311 cell lines), and with a range of sensitivities, are shown in Supplementary Figure 1. This evidence concerns the gene NRAS and melanoma.